Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 201,048 shares, an increase of 2,279.8% from the July 30th total of 8,448 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 399,785 shares, the short-interest ratio is presently 0.5 days.

Sonoma Pharmaceuticals Trading Up 0.7%

Shares of Sonoma Pharmaceuticals stock opened at $1.35 on Wednesday. The company has a 50 day moving average of $1.22 and a 200-day moving average of $1.71. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $4.87. The company has a market cap of $6.46 million, a PE ratio of -1.11 and a beta of 1.28.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.32. The business had revenue of $6.41 million for the quarter, compared to analyst estimates of $4.99 million. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 1.95% of the stock is currently owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.